Correction to: Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer

被引：0
|
作者：
Katherine A. Lyseng-Williamson
机构：
[1] Springer Nature,
来源：
Drugs | 2020年 / 80卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The author has alerted us to the following error.
引用
收藏
页码：2001 / 2001
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer
    Fonseca Magalhaes Filho, Marcos Aurelio
    Aguiar, Pedro Nazareth, Jr.
    Mascarenhas Neves, Milena Brachmans
    Lopes, Gilberto de Lima, Jr.
    del Giglio, Auro
    EINSTEIN-SAO PAULO, 2022, 20 : eGS6655
  • [32] The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer
    Delgado, J.
    Vleminckx, C.
    Sarac, S.
    Sosa, A.
    Bergh, J.
    Giuliani, R.
    Enzmann, H.
    Pignatti, F.
    ESMO OPEN, 2021, 6 (02)
  • [33] Adjuvant Trastuzumab in HER2-Positive Breast Cancer REPLY
    Slamon, Dennis J.
    Buyse, Marc
    Press, Michael F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (07): : 663 - 665
  • [34] Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy
    Molinelli, Chiara
    Parisi, Francesca
    Razeti, Maria Grazia
    Arecco, Luca
    Cosso, Maurizio
    Fregatti, Piero
    Del Mastro, Lucia
    Poggio, Francesca
    Lambertini, Matteo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (03) : 241 - 250
  • [35] Development of trastuzumab emtansine (Kadcyla®) for thetreatment of HER2-positive breast cancer
    Phillips, Gail
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [36] Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
    Sadeghi, Saeed
    Olevsky, Olga
    Hurvitz, Sara A.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 329 - 338
  • [37] Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
    Recondo, Gonzalo, Jr.
    de la Vega, Maximo
    Galanternik, Fernando
    Diaz-Canton, Enrique
    Amadeo Leone, Bernardo
    Leone, Jose Pablo
    CANCER MANAGEMENT AND RESEARCH, 2016, 8 : 57 - 65
  • [38] NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer
    Elsada, Ahmed
    Doss, Sally
    Robertson, Janet
    Adam, E. Jane
    LANCET ONCOLOGY, 2016, 17 (02): : 143 - 144
  • [39] Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptin®) in HER2-positive early breast cancer
    Ewer, M. S.
    Perez, E. A.
    Baselga, J.
    Bell, R.
    Brutsaert, D.
    Marty, M.
    Pienkowski, T.
    Suter, T. M.
    BREAST, 2007, 16 : S63 - S63
  • [40] Adjuvant Trastuzumab for HER2-Positive Early Breast Cancer: A Review of Clinical Data With Nursing Implications
    Palmieri, Frances M.
    Myatt, Charlyn V.
    Perez, Edith A.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2010, 14 (03) : 326 - 336
12345